FT: Pharma payments to U.S. docs hit $150M

A dozen drugmakers have paid 165,000 U.S. doctors nearly $150 million so far this year, the Financial Times finds; last year's total was $437 million for 262,000 doctors. Report

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.